InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
0 hedge funds and large institutions have $0 invested in InVivo Therapeutics Holdings Corp in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $5.22K → $0 (-$5.22K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$5.22K |
| 2 |
VL
Vima LLC
Troy,
Michigan
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| – | -$5.22K | -23,741 | Closed |
|
|
VL
2
Vima LLC
Troy,
Michigan
| – | -$2 | -2 | Closed |
|
NVIV Hedge Fund Activity: Q2 2024 in Review
0 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2024, worth a combined $0 — down 100% from $5.22K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NVIV and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $5.22K sold.
- 0 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2024, down from 4 in Q1 2024.
- Funds reported $0 of InVivo Therapeutics Holdings Corp stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new InVivo Therapeutics Holdings Corp positions in Q2 2024 and 4 closed out, a net change of -4 holders.
- The largest InVivo Therapeutics Holdings Corp seller in Q2 2024 was Goldman Sachs, an estimated $5.22K sold.
Based on aggregated 13F filings for Q2 2024.